Truist Financial Corp Increases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Truist Financial Corp raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 86.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,003 shares of the biotechnology company’s stock after purchasing an additional 1,857 shares during the period. Truist Financial Corp’s holdings in Sarepta Therapeutics were worth $632,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of SRPT. EP Wealth Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $462,000. Wellington Management Group LLP lifted its stake in shares of Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after buying an additional 217,810 shares during the period. Vanguard Group Inc. lifted its stake in shares of Sarepta Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares during the period. GAMMA Investing LLC lifted its stake in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the period. Finally, Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SRPT. Bank of America upped their price objective on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Robert W. Baird upped their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. UBS Group increased their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their price target for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $183.89.

Sarepta Therapeutics Trading Down 0.5 %

NASDAQ SRPT opened at $123.73 on Wednesday. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The company has a market capitalization of $11.70 billion, a price-to-earnings ratio of 1,124.82 and a beta of 0.82. The company’s fifty day moving average price is $129.49 and its two-hundred day moving average price is $132.43.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the firm posted ($0.27) EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, research analysts predict that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.